This is a working overview of AOD9604, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-11 and is reviewed periodically as new material appears.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Duterte and Zimmerman have been on good terms in recent years, with Zimmerman stating: "Yes, [Rodrigo] is really a very good leader. That is all he is. But when it comes to family, he is not capable of taking care of it." His daughter, Sara, characterized her family as "broken", calling her relationship with her father as "not very close" up to the time she became mayor in 2010. Prior to his arrest, Duterte had been living with his common-law wife Cielito "Honeylet" Avanceña, a businesswoman and former nurse, with whom he has one daughter named Veronica ("Kitty"), an American by birth. Duterte has eleven grandchildren, half of whom are Muslims and the other half Christian, and two great-grandchildren. Since 2022, a child named Mira ("Mimi", born 2019) is seen being raised by Duterte and Avanceña alongside Veronica, though there are conflicting reports on whether she is a child or a grandchild of Duterte. Veronica attributes her rose tattoo to Mira. On his paternal side, Duterte shares familial ties with some of the prominent families of the Visayas, particularly the Almendrases and Duranos of Danao, Cebu. His distant uncle, former Senator Alejandro Almendras, was one of his original supporters when he first ran for mayor of Davao City in 1988.
The development of generative AI has raised concerns from governments, businesses, and individuals, resulting in protests, legal actions, calls to pause AI experiments, and actions by multiple governments. In a July 2023 briefing of the United Nations Security Council, Secretary-General António Guterres stated "Generative AI has enormous potential for good and evil at scale", that AI may "turbocharge global development" and contribute between $10 and $15 trillion to the global economy by 2030, but that its malicious use "could cause horrific levels of death and destruction, widespread trauma, and deep psychological damage on an unimaginable scale". In addition, generative AI has a significant carbon footprint.
== Chairman of the Transitional Sovereignty Council (2021–present) == On 25 October 2021, al-Burhan led the October 2021 Sudanese coup d'état to overthrow the civilian government of Prime Minister Abdalla Hamdok. On 21 November 2021, all political prisoners were freed and Abdalla Hamdok was reinstated as prime minister as part of an agreement with the civilian political parties. Hamdok was also allowed to return leading the transitional government. After the coup, Burhan integrated Islamists into sources of power, in particular the SAF. Muslim Brotherhood members who had been active under the Bashir regime became among the principal supporters of al-Burhan and his rule. On 4 December 2021, al-Burhan told Reuters in an interview that the Sudanese military will "exit politics" following the elections scheduled for July 2023, stating, "When a government is elected, I don't think the army, the armed forces, or any of the security forces will participate in politics. This is what we agreed on and this is the natural situation." On 9 December 2021, al-Burhan warned of possible measures against foreign diplomatic missions for their alleged incitement against the Sudanese army. He also reiterated his commitment to the political agreement struck with Prime Minister Hamdok in November 2021. On 20 December 2021, al-Burhan voiced his support for Hamdok, adding that recent appointments had been made as the result of coordination between him and the prime minister and in line with the 21 November 2021 political agreement.
=== Tour === Clipse announced a United States concert tour in promotion of the album on June 9, consisting of twenty-five planned shows from August 3 to September 10. Atlanta hip-hop duo EarthGang is the planned supporting act. Four dates in Europe were added on July 14, extending the tour's window to November 10.
AAA proteins are divided into seven basic clades, based on secondary structure elements included within or near the core AAA fold: clamp loader, initiator, classic, superfamily III helicase, HCLR, H2-insert, and PS-II insert. AAA ATPases assemble into oligomeric assemblies (often homo-hexamers) that form a ring-shaped structure with a central pore. These proteins produce a molecular motor that couples ATP binding and hydrolysis to changes in conformational states that can be propagated through the assembly in order to act upon a target substrate, either translocating or remodelling the substrate. The central pore may be involved in substrate processing. In the hexameric configuration, the ATP-binding site is positioned at the interface between the subunits. Upon ATP binding and hydrolysis, AAA enzymes undergo conformational changes in the AAA-domains as well as in the N-domains. These motions can be transmitted to substrate protein.
Sources: en.wikipedia.org
SNX contains a BAR domain in its C-terminus, which is located between amino acids 256 and 440. Its ability to form coatings in membranes in order to induce their curvature is key in SNX8 participation in tubular structures formation. Furthermore, SNX8 C-terminus contains a threonine in position 452 and a serine in position 456 which can go through post-traductional changes that induces its phosphorylation, resulting in a phosphothreonine and a phosphoserine. Therefore, there are classified as phosphorylation sites. SNX8 has a yeast ortholog protein, the MVP1 encoded by the also homolog gene Mvp1p, which also plays a role by mediating transport of cargo to the vacuolar and lysosomal compartments. For this reason, its investigation can lead to a better understanding of SNX8 functions in human cells.
DT56a has been described in scientific literature as a selective estrogen receptor modulator (SERM)-like compound. Experimental studies have suggested that DT56a may exert agonistic effects on estrogen receptors in bone and brain tissues, while demonstrating limited activity in uterine and breast tissues. Several studies have investigated DT56a in relation to menopausal symptoms and bone health. In vitro studies have also reported stimulation of osteoblast activity in cultured human bone cells. Published studies have additionally suggested that DT56a does not significantly affect circulating hormone levels or blood coagulation parameters. Selective estrogen receptor modulator
miR-324-5p likely regulates cell growth and survival through interaction with multiple pathways. Published research demonstrates that this miRNA interacts with the Hedgehog (HH) signaling pathway via interactions with HH transcription factor Gli1 and HH protein receptor Smo, often contributing to tumorigenesis. miR-324-5p's activating interaction with the protein NfkB also regulates numerous components of cell survival, including cell cycle control, enzyme synthesis, and cell adhesion. In addition, miR-324-5p regulates components of the MAPK pathway, influencing cell growth, proliferation, and survival. Specifically, miR-324-5p downregulates RAF and ERK and is necessary for normal levels of cell growth. Reduced expression leads to increased cell growth and proliferation, and overexpression limits growth, leading to its role in oncogenesis.
28. Adv Gerontol. 2007;20(1):74-85. [Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people]. [Article in Russian] Korkushko OV, Lapin BA, Goncharova ND, Khavinson VKh, Shatilo VB, Vengerin AA, Antoniuk-Shcheglova IA, Magdich LV. In the course of aging both monkeys and people reveal decreased night and average daily level of melatonin in the blood plasma and reduced hormone circadian rhythm amplitude, which evidence the disorder of the pineal gland melatonin releasing function. Peptide preparations of the pineal gland (Epithalamin--a complex of peptides isolated from the pineal gland and Epitalon--synthetic tetrapeptide) recover night release of endogenous melatonin and lead to the normalization of the hormone circadian rhythm in the blood plasma. In elderly people Epithalamin and Epitalon modulate pineal gland functional state: people with pineal gland functional insufficiency report an increase of night melatonin level. The preparations of the pineal gland, effectively increasing melatonin concentration and having no side effects, can be used in clinical geriatric practice.
Sources: en.wikipedia.org
=== Names === Oxitriptan is the generic name of the drug and its INNTooltip International Nonproprietary Name. Brand names of oxitriptan include Cincofarm, Levothym, Levotonine, Oxyfan, Telesol, Tript-OH, and Triptum.
== Pharmacology == The enzymes do not reach the bloodstream in significant amounts and are presumed to largely stay at the point of injection until they are broken down by proteases. The two collagenases act synergistically by cleaving tropocollagen (the 'collagen molecule') at different points. AUX-I attacks the C- and N-termini, AUX-II cleaves amino acid bonds within the molecule. Small collagen fragments are broken down by both enzymes.
A cystocele, also known as a prolapsed bladder, is a medical condition in which a woman's bladder bulges into her vagina. Some may have no symptoms. Others may have trouble starting urination, urinary incontinence, or frequent urination. Complications may include recurrent urinary tract infections and urinary retention. Cystocele and a prolapsed urethra often occur together and is called a cystourethrocele. Cystocele can negatively affect quality of life. Causes include childbirth, constipation, chronic cough, heavy lifting, hysterectomy, genetics, and being overweight. The underlying mechanism involves weakening of muscles and connective tissue between the bladder and vagina. Diagnosis is often based on symptoms and examination. If the cystocele causes few symptoms, avoiding heavy lifting or straining may be all that is recommended. In those with more significant symptoms a vaginal pessary, pelvic muscle exercises, or surgery may be recommended. The type of surgery typically done is known as a colporrhaphy. The condition becomes more common with age. About a third of women over the age of 50 are affected to some degree.
Specific gravity—(using a hydrometer test strip or some sort of floating indicator), Refractometer—which measures the refractive index of the antifreeze solution, and Test strips—specialized, disposable indicators made for this purpose. Both specific gravity and refractive index are affected by temperature, although the former is affected much less catastrophically. Temperature compensation is nevertheless recommended for RI measurement. Propylene glycol solutions cannot be tested using specific gravity because of ambiguous results (40% and 100% solutions have the same specific gravity), although typical uses rarely exceed 60% concentration. The boiling point can be similarly determined by a concentration given from one of the three methods. Datasheets for glycol/water coolant mixtures are commonly available from chemical vendors.
AAS is calculated as mg of limiting amino acid in 1 g of test protein / mg of same amino acid in 1 g of reference protein. FTPD is calculated as PI - (FP - MFP)/PI. PI is protein intake, FP is fecal protein, MFP is metabolic fecal protein (amount of protein in feces on a protein-free diet). The digestibility test is done with rats. Some sources may list AAS and PD separately as percentages.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.